Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...
Stifel raised the firm’s price target on Boston Scientific (BSX) to $120 from $115 and keeps a Buy rating on the shares after having hosted ...
GlobalData on MSN4d
Farapulse boosts Boston Scientific’s Q4 electrophysiology sales by 172%Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.
Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...
Boston Scientific (NYSE:BSX – Get Free Report) had its price objective hoisted by research analysts at Stifel Nicolaus from ...
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even ...
Medical device maker Boston Scientific forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices.
Boston Scientific Co. (NYSE:BSX – Get Free Report) has been given an average recommendation of “Buy” by the twenty-three ...
Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback